Essay Instructions: The assignment is a RESEARCH-BASED POLICY PAPER reviewing the status of resolving the problem/issue, and an well-analyzed proposed solution.
The topic of the POLICY PAPER is: THE STATE OF HIV VACCINE DEVELOPMENT
The policy paper will address the problem (scope, significance, previous attempts at resolving the problem); possible approaches to resolving the problem; and a well-reasoned, analytical argument recommending an approach to resolving the problem.
THIS IS NOT FOR THE PURPOSE OF SUGGESTING HOW SCIENTISTS SHOULD CREATE A VACCINE. THIS IS MORE ABOUT THE VALUE STATEMENT. THIS SHOULD ANALYZE WHETHER THERE IS SUFFICIENT INCENTIVE AMONGST KEY STAKEHOLDERS TO SOLVE THIS PROBLEM ON THE PART OF KEY STAKEHOLDERS (DRUG MANUFACTURERS, GOVTS, NON-PROFITS) AND HOW YOU COULD CHANGE THE VALUE PROP TO INCENTIVIZE STAKEHOLDERS THROUGH PUBLIC PRIVATE PARTNERSHIPS. OFFSET RISKS, INCENT STAKEHOLDERS. Looking for problem, solution, and how policy can play a role. Needs to support solution sufficiently.
HIV vaccine currently includes a lot of collaboration, and that should be covered.
SIMPLIFY VACCINE TO THREE THINGS:
1. ANTIGEN
2. AGAVENT
3. FORMULATIONS (how to formulate the above two things to induce the immune response)
Also consider diagnostics: platform, plastic kits, and reagents (antigens)
drug development: pathway, cost, risks
double-spaced, 12-point Times Roman, 1-inch margins.
The FIRST 2.5 PAGES should outline history and current status, including specific sections on: scope, significance, and previous attempts at resolving. This should be discussed from the perspective described above. This section should be based on scholarly journals and other respected authorities, and not random unsubstantiated internet sites or blog posts, etc. However, this is a paper for a law school class (IP and Global Health) and I have no science background and the language/voice of the paper should not be too technical, but rather the interpretation of an intelligent lay person in common language.
The FOLLOWING FOUR PAGES should cover the well-reasoned analytical argument recommending an approach to solving the problem.
THE FINAL HALF PAGE should be a summary and conclusion.
Bibliography should include at least 20 scholarly journal papers and other substantial sources. The following are articles that must be used:
Strategies for an HIV vaccine
NL Letvin - Journal of Clinical Investigation, 2002 - Am Soc Clin Investig
^ Watkins DI (Mar 2008). "Basic HIV Vaccine Development". Top HIV Med 16 (1): 7?8. ISSN 1542-8826. PMID 18441377. http://www.iasusa.org/pub/topics/2008/issue1/7.pdf.
^ Sekaly RP (January 2008). "The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?". J. Exp. Med. 205 (1): 7?12. doi:10.1084/jem.20072681. ISSN 0022-1007. PMID 18195078. PMC 2234358. http://www.jem.org/cgi/pmidlookup?view=long&pmid=18195078.
#
# ^ Song, Kyung M.; Ostrom, Carol M. (2007-11-08). "Failure of AIDS vaccine punctures soaring hopes". Seattle Times. http://seattletimes.nwsource.com/html/health/2004001162_stepvaccine08m.html. Retrieved 2008-10-29.
#
# ^ "Human trials approval sought for AIDS vaccine". http://communications.uwo.ca/com/western_news/stories/human_trials_approval_sought_for_aids_vaccine_20090630444536/. Retrieved 2009-06-30.
^ Nabel, G. J. (2001). "Challenges and opportunities for development of an AIDS vaccine". Nature 410 (6831): 1002?1007. doi:10.1038/35073500. PMID 11309631 .
^ Kim D, Elizaga M, Duerr A (March 2007). "HIV vaccine efficacy trials: towards the future of HIV prevention". Infect. Dis. Clin. North Am. 21 (1): 201?17, x. doi:10.1016/j.idc.2007.01.006. ISSN 0891-5520. PMID 17502236. http://linkinghub.elsevier.com/retrieve/pii/S0891-5520(07)00008-6.
^ a b Harmon, Katherine (16 November 2009). "Renewed Hope". Scientific American (Scientific American, Inc.) 302 (1): pp. 15?16. January 2010. doi:10.1038/scientificamerican0110-15. ISSN 0036-8733. Archived from the original on 23 December 2009. http://www.webcitation.org/5mEyGfWsP. Retrieved 23 December 2009
^ Iaccino E, Schiavone M, Fiume G, Quinto I, Scala G (Jul 2008). "The aftermath of the Merck's HIV vaccine trial". Retrovirology 5: 56. doi:10.1186/1742-4690-5-56. PMID 18597681. PMC 2483718. http://www.retrovirology.com/content/5//56.
^ Shilts, Randy (1987). And the Band Played On: Politics, People, and the AIDS Epidemic. (2007 ed.). St. Martin's Press. ISBN 0312241356. p. 451